NuSil Technology announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones.
Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil Technology (http://www.nusil.com), a leading formulator and manufacturer of silicone compounds for the healthcare and pharmaceutical industries, announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones effective 1-May-2009. As part of the acquisition, NuSil will begin transitioning the manufacturing of seven key Simethicone products used in pharmaceutical applications. Financial details of the transaction were not disclosed.
"The Bluestar Pharmaceutical Simethicone products are a great complement to the current NuSil Simethicone product line. NuSil's 30 years experience working with healthcare-related materials, including silicones for drug delivery systems and long-term implants, provides us with the working regulatory knowledge needed to support the product line for our customers," said Richard Compton, CEO and co-founder of NuSil. "This acquisition, when combined with our ingestible Simethicone product line that we acquired from GE Advanced Materials in 2004, strengthens our position in the pharmaceutical industry as a leading Simethicone supplier with a broad product offering and global distribution capabilities."
Simethicones are wide spectrum antifoam and defoaming products which have been used successfully in various industries including pharmaceutical, food and cosmetics. In the pharmaceutical industry, Simethicones have shown efficacy as antifoams in processes such as biological fermentations and in the manufacture of antibiotics. Simethicones are also widely used as active pharmaceutical ingredients in anti-flatulent formulations. NuSil's current Simethicone products meet various monographs including the European Pharmacopeia for Simethicone and the United States Pharmacopeia for Simethicone Emulsion (contact NuSil for specific references). As part of this acquisition, NuSil will transfer the manufacturing of the Bluestar Silicones Pharmaceutical Simethicone business to NuSil's FDA registered facility in Bakersfield, California.
NuSil formulates standard and customized silicone products based on the vast, unique array of properties the material provides. Product quality is assured by the company's Quality System, which begins with an effective design protocol and continues up the supply chain from vendor qualification through re-inspection of finished product inventories.
For more information on NuSil's silicones for pharmaceuticals, call 805-684-8780 or visit http://www.nusil.com/simethicone.
About NuSil Silicone Technology
NuSil is a leading formulator of silicone compounds for healthcare, aerospace, electronics and other applications requiring precise, predictable materials performance. ISO-9001 certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and provides on-site, in-person application engineering support worldwide. More information about NuSil Technology can be found at http://www.nusil.com.
# # #
Read the full story at http://www.prweb.com/releases/NuSil/Simethicone/prweb2447954.htm.
Copyright©2009 Vocus, Inc.
All rights reserved